Although our current study focuses primarily on lung adenocarcinoma (LUAD) and identifies PECAM1 as a potential prognostic biomarker, these findings collectively underscore the growing importance of subtype-specific biomarkers in NSCLC. Here, PECAM1 is linked to lung adenocarcinoma.